(MedPage Today) — The use of bispecific antibodies (BsAb) before chimeric antigen receptor T-cell therapy (CAR-T) appeared to be a more optimal treatment sequence than BsAb after CAR-T in patients with relapsed or refractory large B-cell lymphoma…
Running for a cause: Clark One Big Run 2026 marks the road to transform communities
Mark your calendars on May 3 for the comeback of Clark One Big Run this time to be held at...






